Other active comparator
Sulfonylurea
OTHER_ACTIVE_sulfonylurea
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.46 (-0.99 to 0.07) | 0.19 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.38 (-0.90 to 0.17) | 0.19 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.22 (0.39 to 4.07) | 0.15 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.63 (0.42 to 4.86) | 0.18 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.36 (0.00 to 27.09) | 0.51 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.36 (0.00 to 23.99) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.74 (0.55 to 12.88) | 0.24 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.76 (0.49 to 14.70) | 0.25 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.32 (0.05 to 1.43) | 0.80 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.33 (0.05 to 1.56) | 0.86 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.02 (0.00 to 0.15) | 0.99 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.02 (0.00 to 0.15) | 0.99 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.08 (0.01 to 0.38) | 0.97 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.08 (0.01 to 0.45) | 0.96 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.27 (0.10 to 0.66) | 0.95 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.28 (0.10 to 0.69) | 0.96 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.22 (0.02 to 1.12) | 0.89 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.23 (0.02 to 1.29) | 0.85 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.09 (0.00 to 1.05) | 0.89 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.08 (0.00 to 1.02) | 0.85 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.63 (0.04 to 9.91) | 0.53 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.64 (0.04 to 10.67) | 0.46 |